Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 615, S2-S4 (2023)
doi: https://doi.org/10.1038/d41586-023-00648-3
This article is part of Nature Outlook: Chronic kidney disease, an editorially independent supplement produced with the financial support of third parties. About this content.
Updates & Corrections
-
Clarification 27 April 2023: This Outlook article originally stated that SGLT2 inhibitors were first approved in 2013. That date is when they were approved in the United States; they were approved in the European Union in 2012.
References
Meraz-Muñoz, A. Y., Weinstein, J. & Wald, R. Kidney360 2, 1042–1047 (2021).
The EMPA-KIDNEY Collaborative Group. N. Engl. J. Med. 388, 117–127 (2023).
McGuire, D. K. et al. JAMA Cardiol. 6, 148–158 (2021).
Perkovic, V. et al. N. Engl. J. Med. 380, 2295–2306 (2019).
Heerspink, J. L. et al. N. Engl. J. Med. 383, 1436–1446 (2020).
Yau, K. et al. Kidney Int. Rep. 7, 1463–1476 (2022).
Song, C. et al. Am. J. Transplant. 22 (suppl. 3), abstr. 30 (2022).
Menzies, R. I. et al. Am. Soc. Nephrol. abstr. PUB361 (2022).